Stammdaten
Natera, Inc., ein Diagnostikunternehmen, entwickelt und vermarktet molekulare Testdienste weltweit. Das Unternehmen bietet Panorama, einen nicht-invasiven Pränataltest zur Prüfung auf chromosomale Abnormitäten eines Fötus durch einen Blutabstrich der Mutter, ebenso wie Zwillingsschwangerschaften bezüglich Zygosität; Vistara, einen Screening-Test für Einzelgen-Mutationen zur Identifikation von Einzelgen-Störungen; Horizon-Träger-Screening zur Bestimmung des Trägerstatus für verschiedene genetische Erkrankungen; und Spectrum zur Identifikation von chromosomalen Anomalien oder vererbten genetischen Erkrankungen während eines In-vitro-Befruchtungszyklus. Das Unternehmen bietet auch Anora-Fehlgeburtstest-Produkte zur Analyse fetaler Chromosomen zur Bestimmung der Ursache einer Fehlgeburt; und nicht-invasive Vaterschaftstest-Produkte zur Bestimmung der Vaterschaft mittels Schwangerschaft durch einen Blutabstrich von der schwangeren Mutter und dem mutmaßlichen Vater. Zusätzlich bietet es Constellation an, ein cloudbasiertes Softwareprodukt, das Laborkundenlabore befähigt, über die Cloud auf die Algorithmen und Bioinformatik des Unternehmens zuzugreifen, um Tests zu validieren und einzuführen; Signatera, eine zirkulierende Tumor-DNA-Technologie, die auf einen generischen Satz von Mutationen unabhängig vom Tumor eines Individuums prüft; und Prospera zur Bewertung der Transplantatablehnung. Das Unternehmen bietet Produkte über seine direkte Vertriebskraft, sowie über ein Netzwerk von ungefähr 100 Labor- und Vertriebspartnern an. Das Unternehmen hat eine Partnerschaftsvereinbarung mit BGI Genomics Co., Ltd. zur Entwicklung, Herstellung und Vermarktung von NGS-basierten genetischen Test-Assays; und Foundation Medicine, Inc. zur Entwicklung und Vermarktung personalisierter Überwachungs-Assays für zirkulierende Tumor-DNA. Das Unternehmen war früher als Gene Security Network, Inc. bekannt und änderte seinen Namen 2012 in Natera, Inc.. Natera, Inc. wurde 2003 gegründet und hat seinen Sitz in Austin, Texas. KI
Unternehmen & Branche
| Name | Natera, Inc. |
|---|---|
| Ticker | NTRA |
| CIK | 0001604821 |
| Börse | Nasdaq |
| Sektor | Gesundheit |
| Industrie | Diagnostik & Labore |
| SIC | 8071 · Services-Medical Laboratories |
Wertpapier & Kennzahlen
| CUSIP | 632307104 |
|---|---|
| ISIN | US6323071042 |
| Typ | Common Stock |
| Marktkapitalisierung | 35,23 Mrd. USD |
| Beta | 1,51 |
Sitz & Kontakt
| Sitz (Inkorporation) | DE |
|---|---|
| Geschäftsadresse | 13011 MCCALLEN PASS BUILDING A SUITE 100, 78753 AUSTIN, TX |
| Telefon | 650-249-9090 |
| EIN (IRS) | 01-0894487 |
Listing & Historie
| Listing-Börsen | Nasdaq |
|---|---|
| Fiskaljahr-Ende | 31.12. |
| SEC-Filer-Status | Large accelerated filer |
Bewertung
| KBV (P/B) | 20,58 vs. 13,60 (2021) ▲ |
|---|---|
| KUV (P/S) | 15,28 vs. 14,21 (2021) ▲ |
| FCF-Rendite | 0,3 % vs. -4,2 % (2021) ▲ |
Qualität & Bilanz
| Operative Marge | -13,4 % vs. -74,8 % (2021) ▲ |
|---|---|
| Nettomarge | -9,0 % vs. -75,4 % (2021) ▲ |
| ROIC | -10,8 % vs. -44,9 % (2021) ▲ |
| Zinsdeckungsgrad | -76,2 vs. -56,4 (2021) ▼ |
| Forderungslaufzeit (DSO) | 47 T vs. 71 T (2021) ▼ |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | TTM* | Verlauf |
|---|---|---|---|---|---|---|---|
| Bewertung | |||||||
| KBV (P/B) | 13,60 | 6,33 | 9,79 | 17,57 | 18,69 | 19,86 | |
| KUV (P/S) | 14,21 | 5,45 | 6,92 | 12,37 | 13,88 | 14,09 | |
| FCF-Rendite | -4,2 % | -10,7 % | -3,8 % | 0,3 % | 0,3 % | 0,3 % | |
| Qualität & Bilanz | |||||||
| Operative Marge | -74,8 % | -66,0 % | -41,2 % | -13,1 % | -13,4 % | -13,0 % | |
| Nettomarge | -75,4 % | -66,8 % | -40,2 % | -11,2 % | -9,0 % | -9,0 % | |
| ROIC | -44,9 % | -47,6 % | -36,0 % | -13,8 % | -10,8 % | -11,2 % | |
| Zinsdeckungsgrad | -56,4 | -58,1 | -35,3 | -20,8 | -76,2 | – | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
TTM* = letzte zwölf Monate (vorläufig, ungeprüft): jüngstes Geschäftsjahr + laufendes YTD − Vorjahres-YTD aus den Quartalsberichten (10-Q); Bewertungs-Multiples gegen die aktuelle Marktkapitalisierung. Kein testierter Jahresabschluss.
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Glück Conviction Score™ ⓘ
ⓘ
NTRA
Natera, Inc.
Effektiv
Neutral
Handelsvolumen
Hoch
Insider
0,0
Keine Insider-Käufe
Institutionell
42,7
96 neu, 301 erhöht, -3536819K $ netto
Aktivist
16,8
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,71% (Stand: 30.06.2026)
Score-Verlauf (90 Tage)
Konviktions-Verlauf — oben stark · Mitte neutral · unten schwach
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (24 Monate)
Indexierte Darstellung (Start = 100) — die Kursform bleibt sichtbar, absolute Kurse sind angemeldeten Mitgliedern vorbehalten.
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 243.29 | +10.8 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 220.10 | +22.5 % vs SMA200 | |
| SMA-Cross | Bullisch | 10 % | GOLDEN | vor 38 Tagen @ 222.10 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 262.20 | EMA50: 248.15 | |
| MACD-Histogramm | Bärisch | 10 % | -3.122 | Bearisch | |
| RSI(14) | Neutral | 10 % | 57.5 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 63.7 | Neutral | |
| ADX(14)+DI | Neutral | 10 % | 21.0 | +DI: 24.4 / −DI: 18.0 | |
| Z-Score(60) | Neutral | 5 % | 1.10 | In Range | |
| 52W-Position | Bullisch | 5 % | 90.6 % | Hoch 283.80 / Tief 133.66 | |
| Bollinger(20,2σ) | Neutral | 5 % | 50.6 % | Upper 287.00 / Mid 269.46 / Lower 251.91 | |
| LinReg-Slope(60) | Bullisch | 10 % | +1.5401 | R²=0.77 / annualisiert +164.3 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-07-29 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1.863 | 249,38 | -464.594,94 | -65,8% | |
| 2026-07-28 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -170 | 254,33 | -43.236,75 | -6,1% | |
| 2026-07-28 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1.008 | 253,77 | -255.797,34 | -36,2% | |
| 2026-07-28 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1.241 | 254,07 | -315.301,49 | -44,6% | |
| 2026-07-28 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.003 | 254,07 | -254.832,61 | -36,1% | |
| 2026-07-28 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -3.580 | 254,07 | -909.572,03 | -128,8% | |
| 2026-07-28 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -1.204 | 254,07 | -305.900,88 | -43,3% | |
| 2026-07-28 | Fesko John | Officer, PRESIDENT, CHIEF BUS. OFFICER | Open Market Sale | -931 | 254,07 | -236.539,64 | -33,5% | |
| 2026-07-28 | Sheena Jonathan | Director | Open Market Sale | -191 | 254,07 | -48.527,29 | -6,9% | |
| 2026-07-27 | Sheena Jonathan | Director | Open Market Sale | -288 | 260,49 | -75.021,35 | -10,6% | |
| 2026-07-27 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -1.010 | 260,49 | -263.095,71 | -37,2% | |
| 2026-07-27 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -2.190 | 260,49 | -570.474,85 | -80,8% | |
| 2026-07-27 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -884 | 260,49 | -230.273,87 | -32,6% | |
| 2026-07-27 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -782 | 260,49 | -203.703,81 | -28,8% | |
| 2026-07-27 | Fesko John | Officer, PRESIDENT, CHIEF BUS. OFFICER | Open Market Sale | -782 | 260,49 | -203.703,81 | -28,8% | |
| 2026-07-27 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -1.718 | 260,49 | -447.523,19 | -63,3% | |
| 2026-07-15 | Sheena Jonathan | Director | Open Market Sale | -180 | 274,99 | -49.497,44 | -7,0% | |
| 2026-07-15 | Sheena Jonathan | Director | Open Market Sale | -170 | 275,26 | -46.794,95 | -6,6% | |
| 2026-07-15 | Sheena Jonathan | Director | Open Market Sale | -100 | 273,68 | -27.368,40 | -3,9% | |
| 2026-07-15 | Sheena Jonathan | Director | Open Market Sale | -40 | 276,38 | -11.055,20 | -1,6% | |
| 2026-07-15 | Sheena Jonathan | Director | Open Market Sale | -90 | 274,26 | -24.683,30 | -3,5% | |
| 2026-07-15 | Sheena Jonathan | Director | Open Market Sale | -80 | 276,02 | -22.081,20 | -3,1% | |
| 2026-07-15 | Sheena Jonathan | Director | Open Market Sale | -390 | 273,01 | -106.473,43 | -15,1% | |
| 2026-07-15 | Sheena Jonathan | Director | Open Market Sale | -450 | 273,05 | -122.871,29 | -17,4% | |
| 2026-07-15 | Chapman Rowan E | Director | Open Market Sale | -135 | 274,82 | -37.100,70 | -5,3% | |
| 2026-07-13 | Sheena Jonathan | Director | Open Market Sale | -800 | 264,29 | -211.435,52 | -29,9% | |
| 2026-07-13 | Sheena Jonathan | Director | Open Market Sale | -400 | 265,15 | -106.059,52 | -15,0% | |
| 2026-07-13 | Sheena Jonathan | Director | Open Market Sale | -450 | 267,72 | -120.474,72 | -17,1% | |
| 2026-07-13 | Sheena Jonathan | Director | Open Market Sale | -500 | 262,72 | -131.358,00 | -18,6% | |
| 2026-07-13 | Sheena Jonathan | Director | Open Market Sale | -500 | 266,75 | -133.377,00 | -18,9% | |
| 2026-07-13 | Sheena Jonathan | Director | Open Market Sale | -500 | 268,39 | -134.193,50 | -19,0% | |
| 2026-07-06 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -1.000 | 280,00 | -280.000,00 | -39,6% | |
| 2026-07-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.400 | 276,24 | -386.739,50 | -54,7% | |
| 2026-07-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.955 | 278,25 | -543.972,89 | -77,0% | |
| 2026-07-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -2.045 | 277,29 | -567.055,80 | -80,3% | |
| 2026-07-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -3.705 | 268,11 | -993.329,77 | -140,6% | |
| 2026-07-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -100 | 267,19 | -26.718,50 | -3,8% | |
| 2026-07-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -300 | 274,06 | -82.218,00 | -11,6% | |
| 2026-07-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -2.600 | 272,99 | -709.774,00 | -100,5% | |
| 2026-07-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -484 | 269,87 | -130.615,72 | -18,5% | |
| 2026-07-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -454 | 272,14 | -123.551,02 | -17,5% | |
| 2026-07-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -300 | 278,77 | -83.630,01 | -11,8% | |
| 2026-07-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.568 | 266,79 | -418.330,64 | -59,2% | |
| 2026-07-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.932 | 268,99 | -519.694,09 | -73,6% | |
| 2026-07-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.357 | 270,96 | -367.698,83 | -52,0% | |
| 2026-07-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.100 | 275,20 | -302.716,92 | -42,8% | |
| 2026-07-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -500 | 274,19 | -137.095,40 | -19,4% | |
| 2026-06-24 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -5.066 | 252,31 | -1.278.190,30 | -180,9% | |
| 2026-06-24 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -11.130 | 253,39 | -2.820.212,89 | -399,2% | |
| 2026-06-24 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -16.204 | 250,25 | -4.055.036,42 | -574,0% | |
| 2026-06-24 | ROSENMAN HERM | Director | Open Market Sale | -16.530 | 250,00 | -4.132.500,00 | -585,0% | |
| 2026-06-24 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.200 | 251,60 | -301.914,96 | -42,7% | |
| 2026-06-17 | Sheena Jonathan | Director | Open Market Sale | -122 | 220,93 | -26.952,90 | -3,8% | |
| 2026-06-17 | Sheena Jonathan | Director | Open Market Sale | -96 | 219,13 | -21.036,68 | -3,0% | |
| 2026-06-17 | Sheena Jonathan | Director | Open Market Sale | -71 | 220,46 | -15.652,89 | -2,2% | |
| 2026-06-17 | Sheena Jonathan | Director | Open Market Sale | -15 | 222,14 | -3.332,16 | -0,5% | |
| 2026-06-17 | Sheena Jonathan | Director | Open Market Sale | -301 | 221,39 | -66.637,04 | -9,4% | |
| 2026-06-17 | Sheena Jonathan | Director | Open Market Sale | -267 | 218,18 | -58.252,78 | -8,2% | |
| 2026-06-17 | Sheena Jonathan | Director | Open Market Sale | -256 | 218,14 | -55.843,10 | -7,9% | |
| 2026-06-17 | Sheena Jonathan | Director | Open Market Sale | -128 | 219,26 | -28.064,97 | -4,0% | |
| 2026-06-17 | Sheena Jonathan | Director | Open Market Sale | -244 | 221,46 | -54.037,24 | -7,6% | |
| 2026-06-16 | Chapman Rowan E | Director | Open Market Sale | -2.964 | 216,78 | -642.535,92 | -91,0% | |
| 2026-06-15 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -3.811 | 217,60 | -829.283,89 | -117,4% | |
| 2026-06-15 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -1.237 | 211,81 | -262.007,98 | -37,1% | |
| 2026-06-15 | Sheena Jonathan | Director | Open Market Sale | -300 | 213,54 | -64.061,49 | -9,1% | |
| 2026-06-15 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -831 | 209,83 | -174.372,30 | -24,7% | |
| 2026-06-15 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -400 | 218,72 | -87.489,00 | -12,4% | |
| 2026-06-15 | Sheena Jonathan | Director | Open Market Sale | -1.750 | 210,29 | -368.011,18 | -52,1% | |
| 2026-06-15 | Sheena Jonathan | Director | Open Market Sale | -600 | 211,34 | -126.802,50 | -17,9% | |
| 2026-06-15 | Sheena Jonathan | Director | Open Market Sale | -500 | 212,42 | -106.212,00 | -15,0% | |
| 2026-06-15 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -11.877 | 215,91 | -2.564.338,13 | -363,0% | |
| 2026-06-15 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -10.338 | 214,72 | -2.219.747,45 | -314,2% | |
| 2026-06-15 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -7.836 | 213,88 | -1.675.999,73 | -237,2% | |
| 2026-06-15 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -6.741 | 216,81 | -1.461.539,80 | -206,9% | |
| 2026-06-15 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -5.097 | 212,84 | -1.084.826,62 | -153,6% | |
| 2026-06-15 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -1.832 | 210,73 | -386.057,36 | -54,6% | |
| 2026-06-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -5.034 | 213,43 | -1.074.398,57 | -152,1% | |
| 2026-06-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -4.276 | 217,32 | -929.278,28 | -131,5% | |
| 2026-06-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -12.142 | 212,27 | -2.577.401,77 | -364,8% | |
| 2026-06-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -7.182 | 216,51 | -1.554.959,02 | -220,1% | |
| 2026-06-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -5.707 | 214,35 | -1.223.301,16 | -173,2% | |
| 2026-06-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -2.536 | 209,50 | -531.280,08 | -75,2% | |
| 2026-06-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -2.133 | 218,17 | -465.356,61 | -65,9% | |
| 2026-06-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -1.605 | 219,36 | -352.069,75 | -49,8% | |
| 2026-06-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -3.267 | 210,30 | -687.047,81 | -97,3% | |
| 2026-06-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -3.161 | 215,38 | -680.815,23 | -96,4% | |
| 2026-06-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -2.957 | 211,61 | -625.736,98 | -88,6% | |
| 2026-06-05 | Marcus Gail Boxer | Director | Open Market Sale | -4.694 | 217,30 | -1.020.023,10 | -144,4% | |
| 2026-06-05 | Marcus Gail Boxer | Director | Open Market Sale | -3.174 | 218,11 | -692.276,06 | -98,0% | |
| 2026-06-05 | Marcus Gail Boxer | Director | Open Market Sale | -3.016 | 216,06 | -651.646,31 | -92,2% | |
| 2026-06-05 | Marcus Gail Boxer | Director | Open Market Sale | -116 | 218,82 | -25.382,54 | -3,6% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -2.006 | 222,25 | -445.827,28 | -63,1% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -6.751 | 226,15 | -1.526.719,75 | -216,1% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -6.500 | 223,34 | -1.451.680,10 | -205,5% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -5.499 | 216,13 | -1.188.523,07 | -168,2% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -3.409 | 226,97 | -773.740,39 | -109,5% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -2.758 | 219,08 | -604.224,29 | -85,5% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -2.503 | 213,44 | -534.250,33 | -75,6% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -2.400 | 220,19 | -528.450,00 | -74,8% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -2.351 | 217,04 | -510.260,10 | -72,2% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -1.742 | 218,28 | -380.251,95 | -53,8% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -1.630 | 224,99 | -366.736,63 | -51,9% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -1.443 | 223,91 | -323.101,12 | -45,7% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -1.300 | 214,83 | -279.279,00 | -39,5% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -832 | 212,42 | -176.732,36 | -25,0% | |
| 2026-06-01 | BOTHA ROELOF | Director | Open Market Sale | -2.450 | 223,83 | -548.374,93 | -77,6% | |
| 2026-06-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -1.802 | 217,52 | -391.970,86 | -55,5% | |
| 2026-06-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -572 | 220,67 | -126.221,75 | -17,9% | |
| 2026-06-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -413 | 218,84 | -90.382,78 | -12,8% | |
| 2026-06-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -213 | 219,34 | -46.719,42 | -6,6% | |
| 2026-06-01 | BOTHA ROELOF | Director | Open Market Sale | -26.411 | 218,69 | -5.775.771,41 | -817,6% | |
| 2026-06-01 | BOTHA ROELOF | Director | Open Market Sale | -21.304 | 220,94 | -4.706.946,24 | -666,3% | |
| 2026-06-01 | BOTHA ROELOF | Director | Open Market Sale | -14.885 | 221,58 | -3.298.289,75 | -466,9% | |
| 2026-06-01 | BOTHA ROELOF | Director | Open Market Sale | -2.850 | 222,79 | -634.964,04 | -89,9% | |
| 2026-06-01 | BOTHA ROELOF | Director | Open Market Sale | -10.100 | 219,78 | -2.219.745,68 | -314,2% | |
| 2026-05-26 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -1.652 | 202,84 | -335.091,35 | -47,4% | |
| 2026-05-26 | Fesko John | Officer, PRESIDENT, CHIEF BUS. OFFICER | Open Market Sale | -1.438 | 202,84 | -291.683,63 | -41,3% | |
| 2026-05-13 | Sheena Jonathan | Director | Open Market Sale | -290 | 202,58 | -58.748,87 | -8,3% | |
| 2026-05-13 | Sheena Jonathan | Director | Open Market Sale | -285 | 202,68 | -57.764,63 | -8,2% | |
| 2026-05-13 | Sheena Jonathan | Director | Open Market Sale | -96 | 199,43 | -19.145,72 | -2,7% | |
| 2026-05-13 | Sheena Jonathan | Director | Open Market Sale | -85 | 199,52 | -16.958,98 | -2,4% | |
| 2026-05-13 | Sheena Jonathan | Director | Open Market Sale | -30 | 202,84 | -6.085,20 | -0,9% | |
| 2026-05-13 | Sheena Jonathan | Director | Open Market Sale | -360 | 201,19 | -72.429,23 | -10,3% | |
| 2026-05-13 | Sheena Jonathan | Director | Open Market Sale | -9 | 203,30 | -1.829,66 | -0,3% | |
| 2026-05-13 | Sheena Jonathan | Director | Open Market Sale | -345 | 201,11 | -69.384,30 | -9,8% | |
| 2026-05-08 | Sheena Jonathan | Director | Open Market Sale | -700 | 208,13 | -145.690,02 | -20,6% | |
| 2026-05-08 | Sheena Jonathan | Director | Open Market Sale | -200 | 209,57 | -41.914,50 | -5,9% | |
| 2026-05-08 | Sheena Jonathan | Director | Open Market Sale | -200 | 205,43 | -41.086,00 | -5,8% | |
| 2026-05-08 | Sheena Jonathan | Director | Open Market Sale | -900 | 207,24 | -186.516,99 | -26,4% | |
| 2026-05-08 | Sheena Jonathan | Director | Open Market Sale | -1.150 | 210,35 | -241.896,75 | -34,2% | |
| 2026-05-05 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -1.454 | 241,39 | -350.981,06 | -49,7% | |
| 2026-05-05 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -948 | 205,22 | -194.548,56 | -27,5% | |
| 2026-05-05 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -1.697 | 206,77 | -350.888,69 | -49,7% | |
| 2026-05-05 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -2.887 | 206,77 | -596.944,99 | -84,5% | |
| 2026-05-04 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -722 | 206,16 | -148.847,52 | -21,1% | |
| 2026-05-04 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -482 | 210,49 | -101.456,18 | -14,4% | |
| 2026-05-01 | Fesko John | Officer, PRESIDENT, CHIEF BUS. OFFICER | Open Market Sale | -291 | 206,16 | -59.992,56 | -8,5% | |
| 2026-05-01 | Sheena Jonathan | Director | Open Market Sale | -107 | 206,16 | -22.059,12 | -3,1% | |
| 2026-05-01 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -313 | 206,16 | -64.528,08 | -9,1% | |
| 2026-05-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -330 | 206,16 | -68.032,80 | -9,6% | |
| 2026-05-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -150 | 206,93 | -31.039,50 | -4,4% | |
| 2026-05-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -400 | 205,31 | -82.123,00 | -11,6% | |
| 2026-05-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -405 | 206,16 | -83.494,80 | -11,8% | |
| 2026-05-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -505 | 203,32 | -102.674,33 | -14,5% | |
| 2026-05-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -865 | 204,47 | -176.862,83 | -25,0% | |
| 2026-05-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -560 | 200,95 | -112.533,29 | -15,9% | |
| 2026-05-01 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -902 | 206,16 | -185.956,32 | -26,3% | |
| 2026-05-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -520 | 201,60 | -104.832,21 | -14,8% | |
| 2026-04-29 | Sheena Jonathan | Director | Open Market Sale | -805 | 196,99 | -158.575,02 | -22,4% | |
| 2026-04-29 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -200 | 197,26 | -39.452,00 | -5,6% | |
| 2026-04-29 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1.070 | 194,82 | -208.459,54 | -29,5% | |
| 2026-04-29 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -500 | 192,13 | -96.064,30 | -13,6% | |
| 2026-04-29 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -300 | 190,12 | -57.034,50 | -8,1% | |
| 2026-04-29 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1.000 | 193,78 | -193.779,00 | -27,4% | |
| 2026-04-29 | Sheena Jonathan | Director | Open Market Sale | -2.266 | 196,22 | -444.623,42 | -62,9% | |
| 2026-04-27 | Fesko John | Officer, PRESIDENT, CHIEF BUS. OFFICER | Open Market Sale | -771 | 203,75 | -157.091,25 | -22,2% | |
| 2026-04-27 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -3.566 | 204,39 | -728.854,74 | -103,2% | |
| 2026-04-27 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -2.272 | 203,75 | -462.920,00 | -65,5% | |
| 2026-04-27 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -1.185 | 204,39 | -242.202,15 | -34,3% | |
| 2026-04-27 | Fesko John | Officer, PRESIDENT, CHIEF BUS. OFFICER | Open Market Sale | -917 | 204,39 | -187.425,63 | -26,5% | |
| 2026-04-27 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -997 | 203,75 | -203.138,75 | -28,8% | |
| 2026-04-27 | Sheena Jonathan | Director | Open Market Sale | -285 | 203,75 | -58.068,75 | -8,2% | |
| 2026-04-27 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -873 | 203,75 | -177.873,75 | -25,2% | |
| 2026-04-27 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -988 | 204,39 | -201.937,32 | -28,6% | |
| 2026-04-27 | Sheena Jonathan | Director | Open Market Sale | -188 | 204,39 | -38.425,32 | -5,4% | |
| 2026-04-27 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1.222 | 204,39 | -249.764,58 | -35,4% | |
| 2026-04-27 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -771 | 203,75 | -157.091,25 | -22,2% | |
| 2026-04-17 | Sheena Jonathan | Director | Open Market Sale | -750 | 199,66 | -149.748,00 | -21,2% | |
| 2026-04-17 | Sheena Jonathan | Director | Open Market Sale | -750 | 199,59 | -149.692,95 | -21,2% | |
| 2026-04-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.778 | 202,01 | -359.167,02 | -50,8% | |
| 2026-04-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.200 | 203,83 | -244.590,96 | -34,6% | |
| 2026-04-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -300 | 200,79 | -60.236,04 | -8,5% | |
| 2026-04-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -1.048 | 201,32 | -210.983,99 | -29,9% | |
| 2026-04-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -1.000 | 202,36 | -202.363,80 | -28,6% | |
| 2026-04-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.909 | 205,00 | -391.349,96 | -55,4% | |
| 2026-04-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -3.213 | 203,07 | -652.470,34 | -92,4% | |
| 2026-04-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -952 | 203,31 | -193.551,69 | -27,4% | |
| 2026-03-20 | Sheena Jonathan | Director | Open Market Sale | -280 | 200,90 | -56.252,64 | -8,0% | |
| 2026-03-20 | Sheena Jonathan | Director | Open Market Sale | -140 | 199,82 | -27.975,40 | -4,0% | |
| 2026-03-20 | Sheena Jonathan | Director | Open Market Sale | -235 | 198,49 | -46.644,19 | -6,6% | |
| 2026-03-20 | Sheena Jonathan | Director | Open Market Sale | -235 | 199,88 | -46.971,10 | -6,6% | |
| 2026-03-20 | Sheena Jonathan | Director | Open Market Sale | -239 | 198,85 | -47.526,32 | -6,7% | |
| 2026-03-20 | Sheena Jonathan | Director | Open Market Sale | -371 | 200,97 | -74.561,35 | -10,6% | |
| 2026-03-18 | Sheena Jonathan | Director | Open Market Sale | -956 | 197,84 | -189.135,14 | -26,8% | |
| 2026-03-18 | Sheena Jonathan | Director | Open Market Sale | -300 | 196,27 | -58.880,01 | -8,3% | |
| 2026-03-18 | Sheena Jonathan | Director | Open Market Sale | -1.814 | 198,65 | -360.355,09 | -51,0% | |
| 2026-03-16 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -16.457 | 197,22 | -3.245.611,69 | -459,4% | |
| 2026-03-16 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -300 | 190,68 | -57.203,07 | -8,1% | |
| 2026-03-16 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -254 | 198,02 | -50.297,18 | -7,1% | |
| 2026-03-16 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -24.814 | 196,23 | -4.869.290,92 | -689,3% | |
| 2026-03-16 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -100 | 190,07 | -19.007,08 | -2,7% | |
| 2026-03-16 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -900 | 192,43 | -173.185,02 | -24,5% | |
| 2026-03-16 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -2.300 | 194,17 | -446.592,61 | -63,2% | |
| 2026-03-16 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -4.875 | 195,42 | -952.695,90 | -134,9% | |
| 2026-03-13 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -17.037 | 187,63 | -3.196.631,87 | -452,5% | |
| 2026-03-13 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -13.883 | 190,46 | -2.644.206,16 | -374,3% | |
| 2026-03-13 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -21.476 | 188,54 | -4.049.190,27 | -573,2% | |
| 2026-03-13 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -21.504 | 189,50 | -4.075.005,85 | -576,8% | |
| 2026-03-13 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -1.100 | 191,22 | -210.344,97 | -29,8% | |
| 2026-03-13 | Chapman Rowan E | Director | Open Market Sale | -122 | 191,38 | -23.348,36 | -3,3% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
⚠ Vorläufige Daten: Erst 3597 von typischerweise 8414 Fonds (43 %) haben für das aktuelle 13F-Quartal eingereicht — Werte können sich in den kommenden Wochen noch deutlich ändern.
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| JPMORGAN CHASE & CO | 13.386.667 | 0 | 13.386.667 | 2.501.165.314 | Neu | +100,0% | |
| PRICE T ROWE ASSOCIATES INC /MD/ | 12.184.876 | 0 | 12.184.876 | 2.436.855.000 | Neu | +100,0% | |
| BlackRock, Inc. | 10.677.338 | 0 | 10.677.338 | 2.135.360.953 | Neu | +100,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.008.496 | 0 | 6.008.496 | 1.201.639.115 | Neu | +100,0% | |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.644.695 | 0 | 5.644.695 | 1.128.882.553 | Neu | +100,0% | |
| WELLINGTON MANAGEMENT GROUP LLP | 4.768.593 | 0 | 4.768.593 | 953.670.913 | Neu | +100,0% | |
| STATE STREET CORP | 3.417.472 | 0 | 3.417.472 | 683.460.225 | Neu | +100,0% | |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 3.207.366 | 0 | 3.207.366 | 641.441.126 | Neu | +100,0% | |
| Duquesne Family Office LLC | 3.063.606 | 0 | 3.063.606 | 612.691.000 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 2.775.928 | 0 | 2.775.928 | 553.818.995 | Neu | +100,0% | |
| FMR LLC | 2.554.254 | 0 | 2.554.254 | 510.825.126 | Neu | +100,0% | |
| COATUE MANAGEMENT LLC | 2.541.842 | 0 | 2.541.842 | 508.342.981 | Neu | +100,0% | |
| Castle Hook Partners LP | 2.529.810 | 0 | 2.529.810 | 505.936.702 | Neu | +100,0% | |
| FRANKLIN RESOURCES INC | 2.485.325 | 0 | 2.485.325 | 497.040.120 | Neu | +100,0% | |
| AQR CAPITAL MANAGEMENT LLC | 2.273.991 | 0 | 2.273.991 | 442.564.045 | Neu | +100,0% | |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 2.040.106 | 0 | 2.040.106 | 407.990.494 | Neu | +100,0% | |
| FRED ALGER MANAGEMENT, LLC | 1.756.472 | 0 | 1.756.472 | 351.276.835 | Neu | +100,0% | |
| Sofinnova Investments, Inc. | 1.550.280 | 0 | 1.550.280 | 310.040.497 | Neu | +100,0% | |
| NWI MANAGEMENT LP | 1.525.206 | 0 | 1.525.206 | 305.026.000 | Neu | +100,0% | |
| Capital World Investors | 1.467.975 | 0 | 1.467.975 | 293.580.320 | Neu | +100,0% | |
| MORGAN STANLEY | 1.354.335 | 0 | 1.354.335 | 270.853.971 | Neu | +100,0% | |
| Invesco Ltd. | 1.258.377 | 0 | 1.258.377 | 251.662.787 | Neu | +100,0% | |
| RTW INVESTMENTS, LP | 1.250.000 | 0 | 1.250.000 | 249.987.500 | Neu | +100,0% | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.191.732 | 0 | 1.191.732 | 238.334.483 | Neu | +100,0% | |
| MAVERICK CAPITAL LTD | 1.171.633 | 0 | 1.171.633 | 234.314.884 | Neu | +100,0% | |
| T. Rowe Price Investment Management, Inc. | 1.130.820 | 0 | 1.130.820 | 226.153.000 | Neu | +100,0% | |
| LORD, ABBETT & CO. LLC | 1.111.505 | 0 | 1.111.505 | 222.290.000 | Neu | +100,0% | |
| FEDERATED HERMES, INC. | 1.090.030 | 0 | 1.090.030 | 217.995.100 | Neu | +100,0% | |
| Clearbridge Investments, LLC | 893.322 | 0 | 893.322 | 178.655.567 | Neu | +100,0% | |
| Sumitomo Mitsui Trust Group, Inc. | 643.643 | 692.368 | -48.725 | 174.716.892 | Reduziert | -7,0% | |
| VANGUARD FIDUCIARY TRUST CO | 872.640 | 0 | 872.640 | 174.519.274 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 822.831 | 0 | 822.831 | 164.557.971 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 788.445 | 0 | 788.445 | 157.681.116 | Neu | +100,0% | |
| GILDER GAGNON HOWE & CO LLC | 755.275 | 0 | 755.275 | 151.047.391 | Neu | +100,0% | |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 754.729 | 0 | 754.729 | 150.938.268 | Neu | +100,0% | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 752.936 | 0 | 752.936 | 150.579.670 | Neu | +100,0% | |
| PointState Capital LP | 739.879 | 0 | 739.879 | 147.968.401 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 733.669 | 0 | 733.669 | 146.726.383 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 712.748 | 0 | 712.748 | 142.542.473 | Neu | +100,0% | |
| ARK Investment Management LLC | 684.255 | 0 | 684.255 | 136.844.067 | Neu | +100,0% | |
| MAPLELANE CAPITAL, LLC | 474.862 | 0 | 474.862 | 135.793.211 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 631.338 | 0 | 631.338 | 126.261.287 | Neu | +100,0% | |
| Chevy Chase Trust Holdings, LLC | 587.030 | 0 | 587.030 | 117.400.131 | Neu | +100,0% | |
| RAYMOND JAMES FINANCIAL INC | 591.043 | 0 | 591.043 | 112.321.645 | Neu | +100,0% | |
| Robeco Institutional Asset Management B.V. | 408.616 | 405.713 | 2.903 | 110.918.814 | Aufgestockt | +0,7% | |
| FIRST TRUST ADVISORS LP | 528.798 | 0 | 528.798 | 105.754.264 | Neu | +100,0% | |
| VICTORY CAPITAL MANAGEMENT INC | 515.238 | 0 | 515.238 | 103.042.447 | Neu | +100,0% | |
| JANE STREET GROUP, LLC | 499.977 | 0 | 499.977 | 99.990.400 | Neu | +100,0% | |
| Legal & General Group Plc | 498.141 | 0 | 498.141 | 99.623.224 | Neu | +100,0% | |
| AMERICAN CENTURY COMPANIES INC | 496.904 | 0 | 496.904 | 99.375.831 | Neu | +100,0% |
Top-Fondshalter (Stand: 30.06.2026) ⓘ
⚠ Vorläufige Daten: Erst 3597 von typischerweise 8414 Fonds (43 %) haben für dieses Quartal eingereicht. Vollständigkeit erwartet bis 14.08.2026. Auswertungen (NEW/INC/DEC) sind noch zu konservativ — viele Spätfiler erscheinen aktuell als „Exits".
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) | Stimmkontrolle | Verlauf |
|---|---|---|---|---|---|---|---|
| Sumitomo Mitsui Trust Group, Inc. | 643.643 | 692.368 | -7,0% | 174.716.892 | 17,56 | 100 % | 10 Q |
| Robeco Institutional Asset Management B.V. | 408.616 | 405.713 | +0,7% | 110.918.814 | 11,15 | 91 % | 6 Q |
| Assenagon Asset Management S.A. | 250.869 | 60.535 | +314,4% | 68.098.390 | 6,85 | 100 % | 17 Q |
| Handelsbanken Fonder AB | 207.800 | 161.000 | +29,1% | 56.407.000 | 5,67 | 0 % | 17 Q |
| Artemis Investment Management LLP | 200.087 | 191.245 | +4,6% | 54.313.616 | 5,46 | 100 % | 16 Q |
| Erste Asset Management GmbH | 173.011 | 129.500 | +33,6% | 47.112.625 | 4,74 | 100 % | 7 Q |
| Sterling Capital Management LLC | 100.645 | 106.222 | -5,3% | 27.320.085 | 2,75 | 92 % | 8 Q |
| JAG CAPITAL MANAGEMENT, LLC | 86.613 | 85.091 | +1,8% | 23.511.099 | 2,36 | 100 % | 9 Q |
| TRUIST FINANCIAL CORP | 79.524 | 69.015 | +15,2% | 21.586.735 | 2,17 | 3 % | 17 Q |
| NEW YORK STATE COMMON RETIREMENT FUND | 79.147 | 67.847 | +16,7% | 21.484.453 | 2,16 | 100 % | 17 Q |
| PARNASSUS INVESTMENTS, LLC | 77.576 | 74.737 | +3,8% | 21.058.005 | 2,12 | 97 % | 10 Q |
| Pictet Asset Management Holding SA | 50.924 | 48.927 | +4,1% | 13.823.320 | 1,39 | 54 % | 12 Q |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 55.959 | 51.147 | +9,4% | 13.651.708 | 1,37 | 3 % | 11 Q |
| Systrade AG | 50.000 | 50.000 | 0,0% | 13.572.500 | 1,36 | 100 % | 3 Q |
| Asset Management One Co., Ltd. | 48.626 | 48.380 | +0,5% | 13.199.528 | 1,33 | 100 % | 6 Q |
| STRS OHIO | 47.577 | 47.560 | 0,0% | 12.914.777 | 1,30 | 100 % | 11 Q |
| Swedbank AB | 45.534 | 45.534 | 0,0% | 12.360.205 | 1,24 | 100 % | 9 Q |
| FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND | 43.450 | 43.550 | -0,2% | 11.794.503 | 1,19 | 100 % | 6 Q |
| PERKINS CAPITAL MANAGEMENT INC | 40.605 | 44.300 | -8,3% | 11.022.227 | 1,11 | 93 % | 17 Q |
| Resona Asset Management Co.,Ltd. | 36.337 | 38.624 | -5,9% | 9.868.644 | 0,99 | 100 % | 6 Q |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 30.06.2026 | vorl. | 261 | 3,7 | 995 |
| 31.03.2026 | ✓ | 750 | 133,6 | 26.534 |
| 31.12.2025 | ✓ | 767 | 132,6 | 30.380 |
| 30.09.2025 | ✓ | 677 | 141,4 | 22.740 |
| 30.06.2025 | ✓ | 638 | 131,2 | 22.118 |
| 31.03.2025 | ✓ | 587 | 129,4 | 18.294 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 6.008.496 | 1.201.639.115 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.644.695 | 1.128.882.553 |
| VANGUARD FIDUCIARY TRUST CO | 872.640 | 174.519.274 |
| MAPLELANE CAPITAL, LLC | 339.000 | 67.796.611 |
| VANGUARD ASSET MANAGEMENT, Ltd | 226.301 | 45.257.937 |
| CIBC Bancorp USA Inc. | 157.124 | 31.417.629 |
| Avala Global LP | 152.100 | 30.418.479 |
| SEB Asset Management AB | 85.074 | 17.013.934 |
| Vanguard Global Advisers, LLC | 70.081 | 14.015.499 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 69.767 | 13.952.702 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| PRICE T ROWE ASSOCIATES INC /MD/ | 12.184.876 | 1.312.887 | +12.1 % | 2.436.855.000 |
| FMR LLC | 2.554.254 | 1.078.266 | +73.1 % | 510.825.126 |
| Duquesne Family Office LLC | 3.063.606 | 552.249 | +22.0 % | 612.691.000 |
| JPMORGAN CHASE & CO | 13.386.667 | 532.333 | +4.1 % | 2.501.165.314 |
| Castle Hook Partners LP | 2.529.810 | 361.941 | +16.7 % | 505.936.702 |
| Point72 Asset Management, L.P. | 444.199 | 318.887 | +254.5 % | 88.835.358 |
| T. Rowe Price Investment Management, Inc. | 1.130.820 | 304.682 | +36.9 % | 226.153.000 |
| Man Group plc | 265.440 | 240.571 | +967.4 % | 53.085.345 |
| MAVERICK CAPITAL LTD | 1.171.633 | 227.605 | +24.1 % | 234.314.884 |
| FIRST TRUST ADVISORS LP | 528.798 | 209.056 | +65.4 % | 105.754.264 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 3.207.366 | -707.000 | -18.1 % | 641.441.126 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 284.338 | -341.574 | -54.6 % | 56.864.757 |
| AQR CAPITAL MANAGEMENT LLC | 2.273.991 | -325.308 | -12.5 % | 442.564.045 |
| RTW INVESTMENTS, LP | 1.250.000 | -250.000 | -16.7 % | 249.987.500 |
| FRONTIER CAPITAL MANAGEMENT CO LLC | 294.347 | -227.403 | -43.6 % | 58.866.433 |
| TWO SIGMA INVESTMENTS, LP | 40.200 | -227.040 | -85.0 % | 8.039.598 |
| PANAGORA ASSET MANAGEMENT INC | 172.730 | -220.690 | -56.1 % | 34.544.273 |
| Kinetic Partners Management, LP | 60.800 | -212.500 | -77.8 % | 12.159.392 |
| WELLINGTON MANAGEMENT GROUP LLP | 4.768.593 | -207.732 | -4.2 % | 953.670.913 |
| BlackRock, Inc. | 10.677.338 | -182.103 | -1.7 % | 2.135.360.953 |
Zusätzlich aktuell von 303 Mutual Funds/ETFs gehalten (N-PORT). Alle Fondsgesellschaften & ihre 4-Quartals-Bewegungen →
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Δ-Balken |
|---|---|---|---|---|---|---|
| 30.04.2026 | Vanguard Capital Management | Passiv (13G) | 5,08 % | 7.205.939 | Neu | |
| 27.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -9,13 pp | |
| 17.02.2026 | T. Rowe Price Associates, Inc. | Passiv (13G/A) | 7,80 % | 10.872.702 | -1,10 pp | |
| 23.01.2026 | JPMORGAN CHASE & CO. | Passiv (13G/A) | 9,10 % | 12.825.640 | +1,40 pp | |
| 14.08.2025 | T. Rowe Price Associates, Inc. | Passiv (13G/A) | 8,90 % | 12.191.814 | +1,10 pp | |
| 22.07.2025 | JPMORGAN CHASE & CO. | Passiv (13G/A) | 7,70 % | 10.594.256 | +2,70 pp | |
| 14.05.2025 | T. Rowe Price Associates, Inc. | Passiv (13G/A) | 7,80 % | 10.554.721 | +2,70 pp | |
| 17.04.2025 | BlackRock, Inc. | Passiv (13G/A) | 5,60 % | 7.565.936 | Neu | |
| 14.02.2025 | T. Rowe Price Associates, Inc. | Passiv (13G) | 5,10 % | 6.742.428 | Neu | |
| 10.02.2025 | JPMORGAN CHASE & CO. | Passiv (13G) | 5,00 % | 6.668.519 | +0,70 pp | |
| 14.11.2024 | Alger Associates, Inc. 13-3017981 | Passiv (13G/A) | 3,20 % | 4.011.957 | -2,70 pp | |
| 08.11.2024 | . BlackRock, Inc. | Passiv (13G/A) | 6,70 % | 8.237.984 | 0,00 pp | |
| 22.10.2024 | . BlackRock, Inc. | Passiv (13G/A) | 6,70 % | 8.237.984 | +1,50 pp | |
| 07.06.2024 | JPMORGAN CHASE & CO. | Passiv (13G/A) | 4,30 % | 5.335.516 | -2,30 pp | |
| 14.02.2024 | Alger Associates, Inc. 13-3017981 | Passiv (13G/A) | 5,90 % | 7.076.157 | -2,30 pp | |
| 13.02.2024 | The Vanguard Group | Passiv (13G/A) | 9,13 % | 10.971.895 | +0,12 pp | |
| 31.01.2024 | . BlackRock, Inc. | Passiv (13G) | 5,20 % | 6.305.838 | +0,30 pp | |
| 23.01.2024 | JPMORGAN CHASE & CO. | Passiv (13G/A) | 6,60 % | 7.964.473 | +1,00 pp | |
| 06.04.2023 | . BlackRock, Inc. | Passiv (13G/A) | 4,90 % | 5.509.188 | -0,20 pp | |
| 14.02.2023 | Alger Associates, Inc. 13-3017981 | Passiv (13G/A) | 8,20 % | 8.972.721 | +1,00 pp | |
| 09.02.2023 | The Vanguard Group | Passiv (13G/A) | 9,01 % | 9.945.514 | +0,78 pp | |
| 03.02.2023 | . BlackRock, Inc. | Passiv (13G) | 5,10 % | 5.566.743 | +0,20 pp | |
| 23.01.2023 | JPMORGAN CHASE & CO. | Passiv (13G/A) | 5,60 % | 6.211.632 | +0,30 pp | |
| 09.06.2022 | . BlackRock, Inc. | Passiv (13G) | 4,90 % | 4.706.415 | -2,50 pp | |
| 14.02.2022 | Alger Associates, Inc. 13-3017981 | Passiv (13G/A) | 7,20 % | 6.805.028 | -0,08 pp | |
| 10.02.2022 | The Vanguard Group | Passiv (13G/A) | 8,23 % | 7.785.953 | -0,44 pp | |
| 03.02.2022 | . BlackRock, Inc. | Passiv (13G/A) | 7,40 % | 7.010.757 | +0,10 pp | |
| 24.01.2022 | JPMORGAN CHASE & CO. | Passiv (13G) | 5,30 % | 5.025.967 | Neu |
US Congress Trades (STOCK Act)
| Datum | Mitglied | Partei | Kammer | Typ | Betrag-Bereich |
|---|---|---|---|---|---|
| 22.09.2025 | Josh Gottheimer | – | House | Kauf | $1,001 – $15,000 |
| 22.08.2025 | Josh Gottheimer | – | House | Kauf | $1,001 – $15,000 |
| 20.11.2024 | Josh Gottheimer | – | House | Kauf | $1,001 – $15,000 |
Quelle: House eFD & Senate eFD (STOCK Act PTR). Betragsangaben sind Bereichsangaben — keine Exaktwerte. Tiefenanalyse für diese Aktie → · Alle Kongress-Bestände →
Finanzkennzahlen (SEC XBRL) ⓘ
Währung:
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | 696.644.000 $ | -85.091.000 $ | -0,60 $ | 2.614.398.000 $ | 1.774.018.000 $ |
| 2025-12-31 | 10-K | 2.306.113.000 $ | -208.160.000 $ | -1,52 $ | 2.398.344.000 $ | 1.712.413.000 $ |
| 2025-09-30 | 10-Q | 592.183.000 $ | -87.544.000 $ | -0,64 $ | 1.821.482.000 $ | 1.252.188.000 $ |
| 2025-06-30 | 10-Q | 546.600.000 $ | -100.938.000 $ | -0,74 $ | 1.757.066.000 $ | 1.246.182.000 $ |
| 2025-03-31 | 10-Q | 501.830.000 $ | -66.936.000 $ | -0,50 $ | 1.732.366.000 $ | 1.239.675.000 $ |
| 2024-12-31 | 10-K | 1.696.911.000 $ | -190.426.000 $ | -1,53 $ | 1.660.735.000 $ | 1.195.420.000 $ |
| 2024-09-30 | 10-Q | 439.758.000 $ | -31.592.000 $ | -0,26 $ | 1.590.947.000 $ | 878.525.000 $ |
| 2024-06-30 | 10-Q | 413.351.000 $ | -37.464.000 $ | -0,30 $ | 1.516.989.000 $ | 836.520.000 $ |
| 2024-03-31 | 10-Q | 367.741.000 $ | -67.599.000 $ | -0,56 $ | 1.468.205.000 $ | 794.111.000 $ |
| 2023-12-31 | 10-K | 1.082.571.000 $ | -434.801.000 $ | -3,78 $ | 1.441.699.000 $ | 765.327.000 $ |
| 2023-09-30 | 10-Q | 268.306.000 $ | -109.030.000 $ | -0,95 $ | 1.446.520.000 $ | 784.658.000 $ |
| 2023-06-30 | 10-Q | 261.404.000 $ | -110.803.000 $ | -0,97 $ | 1.247.893.000 $ | 596.147.000 $ |
| 2023-03-31 | 10-Q | 241.756.000 $ | -136.937.000 $ | -1,23 $ | 1.318.880.000 $ | 650.573.000 $ |
| 2022-12-31 | 10-K | 820.222.000 $ | -547.799.000 $ | -5,57 $ | 1.394.474.000 $ | 705.744.000 $ |
| 2022-09-30 | 10-Q | 210.637.000 $ | -121.480.000 $ | -1,25 $ | 1.009.112.000 $ | 361.621.000 $ |
| 2022-06-30 | 10-Q | 198.200.000 $ | -145.151.000 $ | -1,50 $ | 1.066.976.000 $ | 444.582.000 $ |
| 2022-03-31 | 10-Q | 194.133.000 $ | -138.595.000 $ | -1,45 $ | 1.144.664.000 $ | 542.335.000 $ |
| 2021-12-31 | 10-K | 625.486.000 $ | -471.716.000 $ | -5,21 $ | 1.236.487.000 $ | 653.304.000 $ |
| 2021-09-30 | 10-Q | 158.116.000 $ | -151.273.000 $ | -1,63 $ | 1.311.374.000 $ | 759.017.000 $ |
| 2021-06-30 | 10-Q | 142.026.000 $ | -116.026.000 $ | -1,32 $ | 849.956.000 $ | 299.110.000 $ |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| Product | 2,3 Mrd. | 1,7 Mrd. | 1,1 Mrd. | 797,3 Mio. | 567,1 Mio. | 99,6 % | +36,2% | |
| Licensing And Other | 10,3 Mio. | 11,8 Mio. | 14,0 Mio. | 22,9 Mio. | 58,3 Mio. | 0,4 % | -13,0% |
Quartalsverlauf
| Segment | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q3 FY2024 | Q2 FY2024 | Q1 FY2024 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Product | 590,2 Mio. | 544,4 Mio. | 500,0 Mio. | 436,1 Mio. | 411,4 Mio. | 364,7 Mio. | 99,7 % | +35,3% | |
| Licensing And Other | 2,0 Mio. | 2,2 Mio. | 1,8 Mio. | 3,6 Mio. | 2,0 Mio. | 3,1 Mio. | 0,3 % | -45,3% |
Regionen
| Region | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| US | 2,3 Mrd. | 1,7 Mrd. | 1,0 Mrd. | 785,8 Mio. | 590,9 Mio. | 98,2 % | +36,6% | |
| Europe Middle East India And Africa | 24,5 Mio. | 23,9 Mio. | 22,8 Mio. | 16,6 Mio. | 20,4 Mio. | 1,1 % | +2,5% | |
| Americas Excluding Us | 9,4 Mio. | 6,6 Mio. | 4,9 Mio. | 3,7 Mio. | 4,0 Mio. | 0,4 % | +41,3% | |
| Other Geographic Areas | 8,0 Mio. | 8,7 Mio. | 7,2 Mio. | 14,0 Mio. | 10,1 Mio. | 0,3 % | -7,5% |
Quartalsverlauf
| Region | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q3 FY2024 | Q2 FY2024 | Q1 FY2024 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|---|
| US | 582,4 Mio. | 537,8 Mio. | 492,3 Mio. | 426,3 Mio. | 404,9 Mio. | 359,4 Mio. | 98,3 % | +36,6% | |
| EMEA | 6,0 Mio. | 5,4 Mio. | 6,0 Mio. | 7,7 Mio. | 5,4 Mio. | 5,2 Mio. | 1,0 % | -22,2% | |
| Other Geographic Areas | 2,3 Mio. | 1,8 Mio. | 1,8 Mio. | 3,8 Mio. | 1,4 Mio. | 1,7 Mio. | 0,4 % | -39,3% | |
| Americas Excluding Us | 1,5 Mio. | 1,6 Mio. | 1,7 Mio. | 2,0 Mio. | 1,6 Mio. | 1,5 Mio. | 0,3 % | -23,9% |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 08.05.2026 | 696,6 Mio. USD | -0,60 |
| Q3 2025 | 30.09.2025 | 07.11.2025 | 592,2 Mio. USD | -0,64 |
| Q2 2025 | 30.06.2025 | 08.08.2025 | 546,6 Mio. USD | -0,74 |
| Q1 2025 | 31.03.2025 | 09.05.2025 | 501,8 Mio. USD | -0,50 |
| Q3 2024 | 30.09.2024 | 12.11.2024 | 439,8 Mio. USD | -0,26 |
| Q2 2024 | 30.06.2024 | 09.08.2024 | 413,4 Mio. USD | -0,30 |
| Q1 2024 | 31.03.2024 | 10.05.2024 | 367,7 Mio. USD | -0,56 |
| Q3 2023 | 30.09.2023 | 09.11.2023 | 268,3 Mio. USD | -0,95 |
| Q2 2023 | 30.06.2023 | 04.08.2023 | 261,4 Mio. USD | -0,97 |
Einreichungs-Historie (10-K / 10-Q / 20-F / 6-K)
SEC-Einreichungs-Historie der letzten sechs Jahre (Datum = US-Kalendertag,
SEC/ET): Quartalsberichte (10-Q) und Jahresberichte (10-K); ausländische
Emittenten (ADR/Foreign Private Issuer) reichen stattdessen Jahresberichte
(20-F/40-F) und Zwischenmitteilungen (6-K) ein — dort liegt im SEC-Index
keine Berichtsperiode vor, Periode und Verzögerung bleiben leer. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht (US) | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 08.05.2026 | 10-Q | 31.03.2026 | 38 Tage | SEC » |
| 27.02.2026 | 10-K | 31.12.2025 | 58 Tage | SEC » |
| 07.11.2025 | 10-Q | 30.09.2025 | 38 Tage | SEC » |
| 08.08.2025 | 10-Q | 30.06.2025 | 39 Tage | SEC » |
| 09.05.2025 | 10-Q | 31.03.2025 | 39 Tage | SEC » |
| 28.02.2025 | 10-K | 31.12.2024 | 59 Tage | SEC » |
| 12.11.2024 | 10-Q | 30.09.2024 | 43 Tage | SEC » |
| 09.08.2024 | 10-Q | 30.06.2024 | 40 Tage | SEC » |
| 10.05.2024 | 10-Q | 31.03.2024 | 40 Tage | SEC » |
| 29.02.2024 | 10-K | 31.12.2023 | 60 Tage | SEC » |
| 09.11.2023 | 10-Q | 30.09.2023 | 40 Tage | SEC » |
| 04.08.2023 | 10-Q | 30.06.2023 | 35 Tage | SEC » |
| 10.05.2023 | 10-Q | 31.03.2023 | 40 Tage | SEC » |
| 01.03.2023 | 10-K | 31.12.2022 | 60 Tage | SEC » |
| 09.11.2022 | 10-Q | 30.09.2022 | 40 Tage | SEC » |
| 05.08.2022 | 10-Q | 30.06.2022 | 36 Tage | SEC » |
| 06.05.2022 | 10-Q | 31.03.2022 | 36 Tage | SEC » |
| 25.02.2022 | 10-K | 31.12.2021 | 56 Tage | SEC » |
| 05.11.2021 | 10-Q | 30.09.2021 | 36 Tage | SEC » |
| 06.08.2021 | 10-Q | 30.06.2021 | 37 Tage | SEC » |
| 07.05.2021 | 10-Q | 31.03.2021 | 37 Tage | SEC » |
| 26.02.2021 | 10-K | 31.12.2020 | 57 Tage | SEC » |
| 06.11.2020 | 10-Q | 30.09.2020 | 37 Tage | SEC » |
| 07.08.2020 | 10-Q | 30.06.2020 | 38 Tage | SEC » |
Kapitalerhöhungen & Emissions-Historie
Emissions-Historie aus den finalen SEC-Prospekten: Börsengang (424B4) und Kapitalerhöhungen (424B5, Folge-/Sekundärplatzierungen). Volumen = Brutto-Erlös (bei Börsengängen zusätzlich der Ausgabepreis). Wiederholte Kapitalerhöhungen deuten auf Verwässerung der Altaktionäre hin.
| Datum (US) | Art | Volumen | |
|---|---|---|---|
| 07.09.2023 | Kapitalerhöhung | $235,9 Mio · $55,00/Aktie | SEC » |
| 16.11.2022 | Kapitalerhöhung | $392,6 Mio · $35,00/Aktie | SEC » |
| 22.07.2021 | Kapitalerhöhung | $508,5 Mio · $113,00/Aktie | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Beträge in US-Dollar.
Proxy-/Governance-Filings
Proxy-Statements (SEC DEF-14A-Familie) der letzten sechs Jahre: reguläre HV-Einladungen zur Aktionärsversammlung, Aktivisten-Proxy-Fights (contested / Non-Management-Solicitation) und M&A-Abstimmungen.
| Datum (US) | Kategorie | HV-Termin (US) | Stichtag (US) | Form | |
|---|---|---|---|---|---|
| 23.04.2026 | HV-Einladung | — | — | DEFA14A | SEC » |
| 23.04.2026 | HV-Einladung | 11.06.2026 Jahres-HV | 15.04.2026 | DEF 14A | SEC » |
| 24.04.2025 | HV-Einladung | — | — | DEFA14A | SEC » |
| 24.04.2025 | HV-Einladung | 12.06.2025 Jahres-HV | 15.04.2025 | DEF 14A | SEC » |
| 05.06.2024 | HV-Einladung | — | — | DEFA14A | SEC » |
| 24.04.2024 | HV-Einladung | — | — | DEFA14A | SEC » |
| 24.04.2024 | HV-Einladung | 12.06.2024 Jahres-HV | 24.04.2024 | DEF 14A | SEC » |
| 20.04.2023 | HV-Einladung | — | — | DEFA14A | SEC » |
| 20.04.2023 | HV-Einladung | 09.06.2023 Jahres-HV | 10.04.2023 | DEF 14A | SEC » |
| 13.04.2022 | HV-Einladung | — | — | DEFA14A | SEC » |
| 13.04.2022 | HV-Einladung | 25.05.2022 Jahres-HV | 01.04.2022 | DEF 14A | SEC » |
| 13.04.2021 | HV-Einladung | — | — | DEFA14A | SEC » |
| 13.04.2021 | HV-Einladung | 25.05.2021 Jahres-HV | 01.04.2021 | DEF 14A | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). HV-Termin = Datum der Aktionärsversammlung, Stichtag (Record Date) = Nachweisstichtag für die Stimmberechtigung (aus dem Dokument extrahiert).
Kritische 8-K Meldungen ⓘ
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (06.07.2026)
HOCH Abgang Schlüsselpersonen (16.06.2026)
HOCH Abgang Schlüsselpersonen (16.06.2026)
HOCH Abgang Schlüsselpersonen (05.06.2026)
HOCH Abgang Schlüsselpersonen (06.07.2026)
HOCH Abgang Schlüsselpersonen (16.06.2026)
HOCH Abgang Schlüsselpersonen (16.06.2026)
HOCH Abgang Schlüsselpersonen (05.06.2026)
| Datum | Meldung | Tags | Schwere | Filing | Auszug |
|---|---|---|---|---|---|
| 06.07.2026 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 16.06.2026 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 16.06.2026 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 05.06.2026 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 01.04.2026 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 18.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 12.03.2025 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 06.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 18.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 21.04.2023 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 23.02.2023 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 15.08.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 15.04.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 14.03.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 10.05.2021 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 23.11.2020 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
8-K-Ereignisse (KI)
🔒 Die vollständige KI-Einordnung je 8-K ist Teil des Kunden-Abos — freischalten.
| Datum | Ereignis | Sentiment | Materialität | Zusammenfassung | Filing |
|---|---|---|---|---|---|
| 06.07.2026 | Personalwechsel | 0,05 | 28 | Boardmitglied Monica Bertagnolli tritt zum 1. Juli 2026 zurück, um ihre neue Position bei der National Academy of Medicine anzunehmen. | SEC |
| 16.06.2026 | HV-Abstimmung | 0,00 | 38 | Aktionäre von Natera billigten am 11. Juni 2026 auf ihrer Jahresversammlung fünf Vorschläge ab, einschließlich einer Änderung des Equity-Inc… 🔒 | SEC |
| 16.06.2026 | Personalwechsel | 0,15 | 30 | Thomas Lynch wurde zum Boardmitglied ernannt. Das Board der Natera, Inc. wurde von elf auf zwölf Mitglieder erweitert (effektiv 2. Juni 2026… 🔒 | SEC |
| 05.06.2026 | Personalwechsel | 0,15 | 22 | Natera erweitert seinen Vorstand von 11 auf 12 Mitglieder und ernennt Thomas Lynch ab 2. Juni 2026 als neues Vorstandsmitglied der Klasse I. | SEC |
| 07.05.2026 | Quartalszahlen | 0,00 | 60 | Natera veröffentlichte Q1-2026-Ergebnisse (bis 31. März 2026) per Pressemitteilung und Präsentation. | SEC |
| 01.04.2026 | Personalwechsel | 0,05 | 30 | Natera ernennt Eric Rubin zum Vorstandsmitglied und erweitert die Boardgröße von zehn auf elf Mitglieder. | SEC |
| 26.02.2026 | Quartalszahlen | 0,00 | 70 | Natera veröffentlichte Pressemitteilung und Investorenpräsentation zu Q4- und Jahresergebnissen 2025 (zum 31. Dezember 2025). | SEC |
| 12.01.2026 | Quartalszahlen | 0,00 | 60 | Natera gab am 11. Januar 2026 vorläufige Geschäftsergebnisse für Q4 und Geschäftsjahr 2025 bekannt. | SEC |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-07-09 | 1 | 274,39 | 274 |
| 2026-07-07 | 33 | 283,80 | 9.365 |
| 2026-07-01 | 104 | 271,45 | 28.231 |
| 2026-06-30 | 121 | 272,31 | 32.950 |
| 2026-06-25 | 1.370 | 259,97 | 356.159 |
| 2026-06-22 | 500 | 231,41 | 115.705 |
| 2026-06-18 | 22 | 226,44 | 4.982 |
| 2026-06-15 | 3.539 | 212,07 | 750.516 |
| 2026-06-12 | 15.326 | 219,23 | 3.359.919 |
| 2026-06-10 | 949 | 222,82 | 211.456 |
| 2026-06-09 | 104 | 213,47 | 22.201 |
| 2026-06-04 | 5.154 | 211,85 | 1.091.875 |
| 2026-06-03 | 5 | 212,73 | 1.064 |
| 2026-06-02 | 2 | 218,81 | 438 |
| 2026-05-29 | 12.831 | 213,94 | 2.745.064 |
| 2026-04-24 | 571 | 201,14 | 114.851 |
| 2026-04-21 | 516 | 207,74 | 107.194 |
| 2026-04-17 | 967 | 196,11 | 189.638 |
| 2026-04-15 | 622 | 214,64 | 133.506 |
| 2026-04-08 | 188 | 209,27 | 39.343 |
| 2026-04-06 | 21 | 207,98 | 4.368 |
| 2026-03-31 | 83.324 | 186,84 | 15.568.256 |
| 2026-03-24 | 6 | 200,09 | 1.201 |
| 2026-03-11 | 834 | 198,95 | 165.924 |
| 2026-03-02 | 7.751 | 208,04 | 1.612.518 |
| 2026-02-10 | 12 | 210,58 | 2.527 |